Skip to content
OpenCapital
Get started

Maravai LifeSciences Holdings, Inc. MRVI Due in more than next 12 months

Other financials

Income statement

See full
Revenue$65.8M+40.5%
Gross profit$33.7M+336%
Operating income-$2.2M+95.6%
Net income-$3.7M+87.5%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$165.9M-41.8%
Total debt$270.9M-17.1%
Total equity$211.6M-29.6%
Total assets$713.2M-25.7%

Cash flow

See full
Operating cash flow$8.7M+192%
CapEx$4.4M-1.4%
Free cash flow$4.2M+130%

Valuation

See full
Market cap$902.74M+204%
Enterprise value$1.01B+198%
P/S4.4×+3.2×

Profitability

See full
Gross margin29.3%-8.0pp
Operating margin-82.2%-16.6pp
Net margin-51.1%-9.9pp
FCF margin-25.7%—

Returns & leverage

See full
Return on equity-40.8%-4.0pp
Debt / equity1.3×+0.2×
Current ratio5.9×-0.1×

Where this comes from

Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.

Tagged under the XBRL concept mrvi:UnrecordedUnconditionalPurchaseObligationDueInMoreThanRolling12Months.

The official record: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Maravai LifeSciences Holdings, Inc.'s due in more than next 12 months.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Maravai LifeSciences Holdings, Inc.'s due in more than next 12 months?
Maravai LifeSciences Holdings, Inc. (MRVI) reported due in more than next 12 months of $4.1M in Q1 2026.